var data={"title":"Bismuth subsalicylate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Bismuth subsalicylate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/7521?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=bismuth-subsalicylate-drug-information\" class=\"drug drug_general\">see &quot;Bismuth subsalicylate: Drug information&quot;</a> and <a href=\"topic.htm?path=bismuth-subsalicylate-patient-drug-information\" class=\"drug drug_patient\">see &quot;Bismuth subsalicylate: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758285\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Bismatrol Maximum Strength [OTC];</li>\n      <li>Bismatrol [OTC];</li>\n      <li>Diotame [OTC] [DSC];</li>\n      <li>Geri-Pectate [OTC];</li>\n      <li>Kao-Tin [OTC];</li>\n      <li>Peptic Relief [OTC];</li>\n      <li>Pepto-Bismol InstaCool [OTC];</li>\n      <li>Pepto-Bismol To-Go [OTC];</li>\n      <li>Pepto-Bismol [OTC];</li>\n      <li>Pink Bismuth [OTC];</li>\n      <li>Stomach Relief Max St [OTC];</li>\n      <li>Stomach Relief Plus [OTC];</li>\n      <li>Stomach Relief [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F987210\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Gastrointestinal Agent, Miscellaneous</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F987222\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=bismuth-subsalicylate-drug-information\" class=\"drug drug_general\">see &quot;Bismuth subsalicylate: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>Multiple concentrations of oral liquid formulations exist; close attention must be paid to the concentration when ordering or administering. Children and adolescents who have or are recovering from chicken pox or flu-like symptoms should not use bismuth subsalicylate due to the association of Reye syndrome. Refer to product specific labeling for approved pediatric ages.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: Dosing presented as mg of bismuth subsalicylate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diarrhea: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children 3 to &lt;12 years (Kliegman 2007): Limited data available: Regular strength: <b>Note: </b>Do not exceed 8 doses/24 hours:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">3 to &lt;6 years: Oral: 87 mg every 30 minutes to 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">6 to &lt;9 years: Oral: 175 mg every 30 minutes to 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">9 to &lt;12 years: Oral: 262 mg every 30 minutes to 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children &ge;12 years and Adolescents: Do not exceed 8 doses/24 hours (regular strength), 4 doses/24 hours (maximum strength)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Regular strength: Oral: 524 mg every 30 minutes to 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Maximum strength: Oral: 1,050 mg every 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dyspepsia </b>(gas, upset stomach, indigestion, heartburn, nausea):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &ge;12 years and Adolescents: Do not exceed 8 doses/24 hours (regular strength), 4 doses/24 hours (maximum strength)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Regular strength: Oral: 524 mg every 30 minutes to 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Maximum strength: Oral: 1,050 mg every 1 hour as needed</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diarrhea, chronic</b>: Limited data available: Oral liquid:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infants &ge;2 months: Oral: 44 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children &lt;2 years: Oral: 44 mg every 4 hours <b>or</b> 87 mg every 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 2 to &lt;3 years: Oral: 87 mg every 4 to 6 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 3 to &lt;4 years: Oral: 87 mg every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Children 4 to 6 years: Oral: 175 mg every 4 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Dosing based on two studies; the first was a prospective, double-blind, placebo-controlled clinical trial of 29 infants and children with chronic diarrhea (&gt;6 weeks); after 7 days of bismuth therapy, patients in the treatment group (n=15, age 2 to 30 months) gained significantly more weight and had significantly improved stool characteristics (consistency/frequency) compared to placebo; to prevent recurrence of symptoms, the authors also suggested tapering the medication at the end of therapy (Gryboski 1985). A second study compared bismuth subsalicylate with cholestyramine; patients were treated with bismuth (n=19) for 7 days; bismuth was found to be as effective as cholestyramine in binding of bile acids and at decreasing stool frequency (Gryboski 1990).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Helicobacter pylori</i>-associated antral gastritis</b>: Limited data available:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children and Adolescents: Oral: 8 mg/kg/day divided 2 times daily for 10 to 14 days; some pediatric trials administered in divided doses 4 times daily. <b>Note</b>: Administered as part of triple or quadruple therapy. (Choi 2006; ESPGHAN/NASPGHAN [Koletzko 2011]; Gold 2000).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult:<b> Diarrhea/dyspepsia:</b> Oral: ~525 mg every 30 to 60 minutes or 1,050 mg every 60 minutes as needed for up to 2 days; maximum daily dose: ~4,200 mg [8 doses (regular strength); 4 doses (maximum strength)/24 hours]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. Avoid use in patients with renal failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment: </b>There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758340\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bismatrol Maximum Strength: 525 mg/15 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; wintergreen flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Pectate: 262 mg/15 mL (355 mL) [contains fd&amp;c red #40]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol: 262 mg/15 mL (118 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; original flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 525 mg/15 mL (237 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief Max St: 525 mg/15 mL (237 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief Plus: 525 mg/15 mL (240 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Oral, as subsalicylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bismatrol: 262 mg/15 mL (236 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; wintergreen flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Geri-Pectate: 262 mg/15 mL (355 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Kao-Tin: 262 mg/15 mL (236 mL, 473 mL) [contains fd&amp;c red #40, saccharin sodium, sodium benzoate]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peptic Relief: 262 mg/15 mL (237 mL) [sugar free; contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium; mint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol: 262 mg/15 mL (473 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg/15 mL (236 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg/15 mL (237 mL) [contains benzoic acid, d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 262 mg/15 mL (237 mL, 355 mL) [contains d&amp;c red #22 (eosine), saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 527 mg/30 mL (240 mL, 480 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol InstaCool: 262 mg [sugar free; contains saccharin sodium; peppermint flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Stomach Relief: 262 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 262 mg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Tablet Chewable, Oral, as subsalicylate: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Bismatrol: 262 mg [contains aspartame]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Diotame: 262 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peptic Relief: 262 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Peptic Relief: 262 mg [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pepto-Bismol To-Go: 262 mg [sugar free; contains fd&amp;c red #40 aluminum lake, saccharin sodium; cherry flavor]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Pink Bismuth: 262 mg [contains saccharin sodium]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 262 mg</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758288\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27767312\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Liquid: Shake well before using.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets, chewable: Chew or allow to dissolve in mouth before swallowing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Tablets, nonchewable caplets: Swallow whole with a full glass of water.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F30124378\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store at room temperature. Avoid excessive heat. Protect from freezing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F987211\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Relief of diarrhea and dyspepsia (gas, upset stomach, indigestion, heartburn, nausea) (OTC products: FDA approved in ages &ge;12 years and adults); has also been used for treatment of<i> Helicobacter pylori</i>-associated antral gastritis.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Note:</b> Approved ages and uses for generic products may vary; consult product labeling for specific information.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758283\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Kaopectate may be confused with Kayexalate</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Maalox Total  Relief is a different formulation than other Maalox liquid antacid products which contain aluminum hydroxide, magnesium hydroxide, and simethicone.</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Canadian formulation of Kaopectate does not contain bismuth; the active ingredient in the Canadian formulation is attapulgite.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758305\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Subsalicylate formulation: </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Anxiety, confusion, depression, headache, slurred speech</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Fecal discoloration (grayish black; impaction may occur in infants and debilitated patients), tongue discoloration (darkening)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Neuromuscular &amp; skeletal: Muscle spasm, weakness </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Otic: Hearing loss, tinnitus</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758300\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">OTC labeling: When used for self-medication, do not use if you are allergic to salicylates or are taking other salicylates; have an ulcer, bleeding problem or bloody/black stool</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758301\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Neurotoxicity: Bismuth products may be neurotoxic with very large doses. </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage forms</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain sodium benzoate/benzoic acid; benzoic acid (benzoate) is a metabolite of benzyl alcohol;  large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse  (AAP [&quot;Inactive&quot; 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol derivative with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Self-medication (OTC use): Children and teenagers who have or are recovering from chickenpox or flu-like symptoms should not use subsalicylate. Changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; patients should be instructed to contact their health care provider if these occur. A temporary harmless darkening of the stool and/or tongue may occur with use. Contact a health care provider before use if fever or mucus in the stool occurs. Discontinue use and contact health care provider if any of the following occur: diarrhea lasts &gt;2 days or other symptoms lasts &gt;14 days, diarrhea with a fever, symptoms get worse, hearing loss, or ringing in the ears.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49309059\" class=\"block add-pediatric-warn-info drugH1Div\"><span class=\"drugH1\">Warnings: Additional Pediatric Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Do not use aspirin-containing products in children and adolescents who have or who are recovering from chickenpox or flu symptoms (due to the association with Reye syndrome); when using aspirin, changes in behavior (along with nausea and vomiting) may be an early sign of Reye syndrome; instruct patients and caregivers to contact their health care provider if these symptoms occur.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758310\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758307\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=101045&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the adverse/toxic effect of Salicylates. Increased risk of bleeding may result.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ajmaline: Salicylates may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ammonium Chloride: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Angiotensin-Converting Enzyme Inhibitors: Salicylates may enhance the nephrotoxic effect of Angiotensin-Converting Enzyme Inhibitors. Salicylates may diminish the therapeutic effect of Angiotensin-Converting Enzyme Inhibitors. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Anticoagulants: Salicylates may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benzbromarone: Salicylates may diminish the therapeutic effect of Benzbromarone. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bismuth Subcitrate: Bismuth-Containing Compounds may enhance the neurotoxic effect of Bismuth Subcitrate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Glucose Lowering Agents: Salicylates may enhance the hypoglycemic effect of Blood Glucose Lowering Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbonic Anhydrase Inhibitors: Salicylates may enhance the adverse/toxic effect of Carbonic Anhydrase Inhibitors. Salicylate toxicity might be enhanced by this same combination.  Management: Avoid these combinations when possible.Dichlorphenamide use with high-dose aspirin as contraindicated.  If another combination is used, monitor patients closely for adverse effects.  Tachypnea, anorexia, lethargy, and coma have been reported.<b> Exceptions: </b>Brinzolamide; Dorzolamide.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): Salicylates may enhance the adverse/toxic effect of Corticosteroids (Systemic). These specifically include gastrointestinal ulceration and bleeding. Corticosteroids (Systemic) may decrease the serum concentration of Salicylates. Withdrawal of corticosteroids may result in salicylate toxicity. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dexketoprofen: Salicylates may enhance the adverse/toxic effect of Dexketoprofen. Dexketoprofen may diminish the therapeutic effect of Salicylates. Salicylates may decrease the serum concentration of Dexketoprofen.  Management: The use of high-dose salicylates (3 g/day or more in adults) together with dexketoprofen is inadvisable. Consider administering dexketoprofen 30-120 min after or at least 8 hrs before cardioprotective doses of aspirin to minimize any possible interaction.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ginkgo Biloba: May enhance the anticoagulant effect of Salicylates. Management: Consider alternatives to this combination of agents. Monitor for signs and symptoms of bleeding (especially intracranial bleeding) if salicylates are used in combination with ginkgo biloba.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Anticoagulant/Antiplatelet Properties) (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Salicylates. Bleeding may occur.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hyaluronidase: Salicylates may diminish the therapeutic effect of Hyaluronidase.  Management: Patients receiving salicylates (particularly at larger doses) may not experience the desired clinical response to standard doses of hyaluronidase.  Larger doses of hyaluronidase may be required.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Influenza Virus Vaccine (Live/Attenuated): May enhance the adverse/toxic effect of Salicylates. Specifically, Reye's syndrome may develop.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: Salicylates may diminish the diuretic effect of Loop Diuretics. Loop Diuretics may increase the serum concentration of Salicylates. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Salicylates may increase the serum concentration of Methotrexate. Salicylate doses used for prophylaxis of cardiovascular events are not likely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nonsteroidal Anti-Inflammatory Agents (Nonselective): May enhance the adverse/toxic effect of Salicylates. An increased risk of bleeding may be associated with use of this combination. Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the cardioprotective effect of Salicylates. Salicylates may decrease the serum concentration of Nonsteroidal Anti-Inflammatory Agents (Nonselective).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Potassium Phosphate: May increase the serum concentration of Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">PRALAtrexate: Salicylates may increase the serum concentration of PRALAtrexate. Salicylate doses used for prophylaxis of cardiovascular events are unlikely to be of concern. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: Salicylates may diminish the therapeutic effect of Probenecid. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Salicylates: May enhance the anticoagulant effect of other Salicylates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfinpyrazone: Salicylates may decrease the serum concentration of Sulfinpyrazone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tetracyclines: Bismuth Subsalicylate may decrease the serum concentration of Tetracyclines.  Management: Consider dosing tetracyclines 2 hours before or 6 hours after bismuth. The need to separate doses during Helicobacter pylori eradication regimens is questionable.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Thrombolytic Agents: Salicylates may enhance the adverse/toxic effect of Thrombolytic Agents. An increased risk of bleeding may occur. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Valproate Products: Salicylates may increase the serum concentration of Valproate Products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Varicella Virus-Containing Vaccines: Salicylates may enhance the adverse/toxic effect of Varicella Virus-Containing Vaccines. Reye's Syndrome may develop. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Salicylates may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758298\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Following oral administration, bismuth and salicylates cross the placenta. The use of salicylates in pregnancy may adversely affect the newborn (Lione, 1988). Use during pregnancy is not recommended (Mahadevan 2007).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758316\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Bismuth subsalicylate exhibits both antisecretory and antimicrobial action. This agent may provide some anti-inflammatory action as well. The salicylate moiety provides antisecretory effect and the bismuth exhibits antimicrobial directly against bacterial and viral gastrointestinal pathogens.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758318\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Bismuth: &lt;1%; Subsalicylate: &gt;80%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: Salicylate: V<sub>d</sub>: 170 mL/kg</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding, plasma: Bismuth and salicylate: &gt;90%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Bismuth subsalicylate is converted to bismuth and salicylic acid in the GI tract.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: Bismuth: 21 to 72 days; Salicylate: 2 to 5 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Bismuth: Urine and biliary; Salicylate: Urine (10% excreted unchanged)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758342\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Chewable</b> (Bismuth Subsalicylate Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">262 mg (30): $1.92</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Kao-Tin Oral)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">262 mg/15 mL (236 mL): $3.40</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27758344\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Bisbacter (CO);</li>\n      <li>Bismucar (PE);</li>\n      <li>Bismutol (EC);</li>\n      <li>Bitni X Forte Suspension (IL);</li>\n      <li>Facidmol (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Gastro-Bismol (TH);</li>\n      <li>Gastro-Bismol L (TH);</li>\n      <li>Kalbeten (IL);</li>\n      <li>Peptolite (IL);</li>\n      <li>Pink Bismuth (IL);</li>\n      <li>Stobiol (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bar-Oz B, Bulkowstein M, Benyamini L, et al, &quot;Use of Antibiotic and Analgesic Drugs During Lactation,&quot; <i>Drug Saf</i>, 2003, 26(13):925-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/14583068/pubmed\" target=\"_blank\" id=\"14583068\">14583068</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bismatrol Maximum Strength (bismuth subsalicylate) liquid [product labeling]. Livonia, MI: Major; April 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol--United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. Available at: <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Choi J, Jang JY, Kim JS, Park HY, Choe YH, Kim KM. Efficacy of two triple eradication regimens in children with Helicobacter pylori infection. <i>J Korean Med Sci</i>. 2006;21(6):1037-1040.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/17179683/pubmed\" target=\"_blank\" id=\"17179683\">17179683</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gold BD, Colletti RB, Abbott M, et al. Helicobacter pylori infection in children: recommendations for diagnosis and treatment. <i>J Pediatr Gastroenterol Nutr</i>. 2000;31(5):490-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/11144432/pubmed\" target=\"_blank\" id=\"11144432\">11144432</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gryboski JD, Hillemeier AC, Grill B, Kocoshis S. Bismuth subsalicylate in the treatment of chronic diarrhea of childhood. <i>Am J Gastroenterol</i>. 1985;80(11):871-876.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/3901731/pubmed\" target=\"_blank\" id=\"3901731\">3901731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Gryboski JD, Kocoshis S. Effect of bismuth subsalicylate on chronic diarrhea in childhood: a preliminary report. <i>Rev Infect Dis</i>. 1990;12 Suppl 1:S36-40.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/2305176/pubmed\" target=\"_blank\" id=\"2305176\">2305176</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ingestion of bismuth-containing ointment by a breast-fed infant. <i>Mt Sinai J Med</i>. 1974;41(3):498-501.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/4545567/pubmed\" target=\"_blank\" id=\"4545567\">4545567</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. <i>J Pediatr</i>. 1993;123(1):53-58.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/8320625/pubmed\" target=\"_blank\" id=\"8320625\">8320625</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kleigman R, Nelson W. <i>Nelson Textbook of Pediatrics</i>. 18th ed. Philadelphia, PA: Saunders; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Koletzko S, Jones NL, Goodman KJ, et al. Evidence-based guidelines from ESPGHAN and NASPGHAN for Helicobacter pylori infection in children. <i>J Pediatr Gastroenterol Nutr</i>. 2011;53(2):230-243.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/21558964/pubmed\" target=\"_blank\" id=\"21558964\">21558964</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lione A, &quot;Nonprescription Drugs as a Source of Aluminum, Bismuth, and Iodine During Pregnancy,&quot; <i>Reprod Toxicol</i>, 1987-8, 1(4):243-52.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/2980389/pubmed\" target=\"_blank\" id=\"2980389\">2980389</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U, &quot;Gastrointestinal Medications in Pregnancy,&quot; <i>Best Pract Res Clin Gastroenterol</i>, 2007, 21(5):849-77.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/bismuth-subsalicylate-pediatric-drug-information/abstract-text/17889812/pubmed\" target=\"_blank\" id=\"17889812\">17889812</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peptic Relief (bismuth subsalicylate) chewable tablets [product labeling]. Livonia, MI: Rugby; October 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peptic Relief (bismuth subsalicylate) liquid [product labeling]. Livonia, MI: Rugby; September 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pepto bismol (bismuth subsalicylate) caplet [product labeling]. Cincinnati, OH Procter &amp; Gamble July 2008</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 101045 Version 67.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F27758285\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F987210\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F987222\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F27758340\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F27758288\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F27767312\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F30124378\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F987211\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F27758283\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F27758305\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F27758300\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F27758301\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Warnings: Additional Pediatric Considerations\" href=\"#F49309059\" class=\"outlineLink\">Warnings: Additional Pediatric Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F27758310\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F27758307\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F27758298\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F27758316\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F27758318\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F27758342\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27758344\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/101045|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=bismuth-subsalicylate-drug-information\" class=\"drug drug_general\">Bismuth subsalicylate: Drug information</a></li><li><a href=\"topic.htm?path=bismuth-subsalicylate-patient-drug-information\" class=\"drug drug_patient\">Bismuth subsalicylate: Patient drug information</a></li></ul></div></div>","javascript":null}